Regeneron Pharmaceuticals, Inc. (REGN) is a Healthcare stock tracked by StreetAlpha. REGN reports earnings on Fri, Oct 30, 2026. The average 12-month price target from 11 analysts is $837.09, with a high of $1030.00 and a low of $740.00. Analyst consensus is Buy, based on the latest ratings from 11 firms (6 buy, 5 hold, 0 sell). Over the past 90 days StreetAlpha recorded 7 whale options trades in REGN, 29% of them bullish and 71% bearish. In the past 30 days there were 10 dark pool prints totaling $13.4M, the largest $2.5M.
Each firm's latest rating on REGN in the past 90 days
Average 12-month target
$837.09
Based on 11 analysts who set a price target on REGN in the past 90 days. The average target is $837.09, with a high of $1030.00 and a low of $740.00.
Low $740.00Avg $837.09High $1030.00
Highest target$1030.00
Average target$837.09
Lowest target$740.00
Latest rating changes
RBC CapitalTarget raised
Oct 8Hold$737 → $810
Truist SecuritiesTarget raised
Oct 7Buy$772 → $780
Morgan StanleyTarget raised
Oct 7Hold$758 → $779
JefferiesMaintained
Oct 1Buy$930
Argus ResearchUpgrade
Oct 1Buy$850
Date
Firm
Action
Rating
Price target
Oct 8
RBC Capital
Target raised
Hold
$737 → $810
Oct 7
Truist Securities
Target raised
Buy
$772 → $780
Oct 7
Morgan Stanley
Target raised
Hold
$758 → $779
Oct 1
Jefferies
Maintained
Buy
$930
Oct 1
Argus Research
Upgrade
Buy
$850
Loading…
Whale Options Flow
90D
Total alerts
7
Bullish
2
29%
Bearish
5
71%
Date span
Jul 28 – Sep 29
Loading…
Dark Pool
30D
Prints
10
Notional
$13.4M
Largest print
$2.5M
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether REGN is in one of them and how their past REGN trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
